Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06510582 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Study acronym: CHAI
StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase changed: Phase 1/2 → Phase 1 Final enrollment: 10 participants — 7% of the 140 planned · Trial completed · Primary completion date changed from estimate of Jun 2028 to Jul 27, 2026 · 8 more Show 11 more changesShow less
    • Final enrollment: 10 participants — 7% of the 140 planned
    • Trial completed
    • Primary completion date changed from estimate of Jun 2028 to Jul 27, 2026
    • Trial arms changed: 4 → 2
    • Study completion date changed from estimate of Jun 2028 to Sep 28, 2026
    • Interventions: Bevacizumab 2 mg/kg (Drug), Bevacizumab 4 mg/kg (Drug) to Bevacizumab 2 mg/kg (Drug), Bevacizumab 4 mg/kg (Drug)
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 1 of 7 entries
    • Study description expanded, about 22 words
    • Site details revised
    • Publications: 2 to 3
  2. Primary and study completion dates: Jun 17, 2028 to Jun 2028 Secondary endpoints: 10 to 7 · Site contact updated · Collaborators expanded, about 6 wordsv3 Show 3 more changesShow less
    • Secondary endpoints: 10 to 7
    • Site contact updated
    • Collaborators expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  3. Secondary endpoints: details revised at 5 of 10 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?
Trial Details
NCT Number NCT06510582
Lead Sponsor The Cooper Health System
Collaborators: Society of Vascular and Interventional Neurology
Conditions Chronic Subdural Hematoma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov